MDV3100 shows survival benefit in Phase III AFFIRM trial

According to a Reuters report and a media release this morning, Medivation has announced that interim results of the Phase III AFFIRM trial showed a 4.8-month survival benefit for treatment with MDV3100 compared to a placebo in men with metastatic, castration-resistant prostate cancer after treatment with docetaxel-based chemotherapy. … READ MORE …

MDV3100 Phase III trial starts to enroll patients

According to an e-mail from our friends at Us TOO the AFFIRM trial (A study evaluating the eFFicacy and safety of Investigational dRug MDV3100 in men with advanced prostate cancer) has started to enroll patients in the USA. It had started to enroll patients in Europe earlier this month. … READ MORE …